ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2014
[The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Clinical significance of miRNAs and exosomal miRNAs in non-small cell lung cancer: diagnostic, prognostic, and therapeutic perspectives.Journal of human genetics · 2026Review
- Tumor cell plasticity in non-small cell lung cancer: the role of microRNA and implications for diagnosis, prognosis and treatment.Translational cancer research · 2026Review
- MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy.Journal of applied genetics · 2023Review
- MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.International journal of molecular sciences · 2022Review
- Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.International journal of molecular sciences · 2021Article
- The Roles of MicroRNA in Lung Cancer.International journal of molecular sciences · 2019Review
- Non-coding RNA in drug resistance of hepatocellular carcinoma.Bioscience reports · 2018Review
- microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.Experimental and therapeutic medicine · 2018Article
- Pathophysiological Functions of Rnd3/RhoE.Comprehensive Physiology · 2015Review
- Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.Oncotarget · 2015Article
- [Advances in tumor chemo-resistance regulated by MicroRNA].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveCisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance. Recent researches showed that miRNA could regulate cell growth, apoptosis, migration and invasion even in drug therapy in cancer by its target gene. The aim of this study is to investigate the effects and molecular mechanisms of miR-503 on reversing the cisplatin-resistance in lung cancer DDP-resistant cell line A549/DDP.
methodsMTS assay was employed to determine the effect of miR-503 on A549/DDP' sensitivity to cisplatin. Apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry, the expression of multi-drugs resistant proteins MDR1 and MRP1, ERCC1, RhoE, Survivin and Bcl-2 were determined by Western blot and real time PCR. The phosphorylation of Akt was analyzed by Western blot, the transcriptional activities of NF-κB and AP-1 were detected by dual-luciferase reporter gene systems.
resultsMiR-503 was able to increase the cisplatin sensitivity of A549/DDP. After treatment with miR-503, the reverse folds (RF) to cisplatin was 2.48 fold, the intracellular level of Rh-123 was 2.49 fold, the apoptosis rate was 10.3 fold, the expressions of several drug-resistant related proteins, such as MDR1, MRP1, ERCC1, Survivin and Bcl-2 were downregulated significantly, as shown by WB, in contrast, the level of RhoE was elevated, the mRNA epression of MDR1 was 18.5%, the mRNA epression of MRP1 was 22.3%, the mRNA epression of ERCC1 was 18.6%, the mRNA epression of Survivin was 42.8%, the mRNA expression of Bcl-2 was 68.1%, the mRNA epression of RhoE was 206.5%, in addition, the phosphorylation of Akt decreased and transcriptional activities of NF-κB was 53.7%, AP-1 was 47.4% compared with control group.
conclusionsMiR-503 was able to reverse the cisplatin resistance of A549/DDP. MiR-503 processed this kind of effect by inhibiting the drug efflux, downregulating the expression of drug-resistant related proteins and promoting cell apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.